HK1176015A1 - Therapeutic use of protein polymer conjugates - Google Patents

Therapeutic use of protein polymer conjugates

Info

Publication number
HK1176015A1
HK1176015A1 HK13103501.1A HK13103501A HK1176015A1 HK 1176015 A1 HK1176015 A1 HK 1176015A1 HK 13103501 A HK13103501 A HK 13103501A HK 1176015 A1 HK1176015 A1 HK 1176015A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic use
polymer conjugates
protein polymer
protein
conjugates
Prior art date
Application number
HK13103501.1A
Other languages
English (en)
Chinese (zh)
Inventor
.林
.威德曼
Original Assignee
藥華醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 藥華醫藥股份有限公司 filed Critical 藥華醫藥股份有限公司
Publication of HK1176015A1 publication Critical patent/HK1176015A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK13103501.1A 2009-12-10 2013-03-20 Therapeutic use of protein polymer conjugates HK1176015A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28541109P 2009-12-10 2009-12-10
PCT/US2010/059714 WO2011072138A2 (en) 2009-12-10 2010-12-09 Therapeutic use of protein-polymer conjugates

Publications (1)

Publication Number Publication Date
HK1176015A1 true HK1176015A1 (en) 2013-07-19

Family

ID=44146181

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13103501.1A HK1176015A1 (en) 2009-12-10 2013-03-20 Therapeutic use of protein polymer conjugates

Country Status (32)

Country Link
US (1) US8617532B2 (xx)
EP (1) EP2509593B1 (xx)
JP (1) JP5547816B2 (xx)
KR (1) KR101782084B1 (xx)
CN (1) CN102724980B (xx)
AR (1) AR079369A1 (xx)
AU (1) AU2010328067B2 (xx)
BR (1) BR112012014017B1 (xx)
CA (1) CA2782624C (xx)
CL (1) CL2012001503A1 (xx)
CY (1) CY1122901T1 (xx)
DK (1) DK2509593T3 (xx)
EA (1) EA022354B9 (xx)
ES (1) ES2786025T3 (xx)
HK (1) HK1176015A1 (xx)
HR (1) HRP20200678T1 (xx)
HU (1) HUE049051T2 (xx)
IL (1) IL220249A0 (xx)
LT (1) LT2509593T (xx)
MA (1) MA33913B1 (xx)
MX (1) MX337705B (xx)
MY (1) MY169961A (xx)
NZ (1) NZ600528A (xx)
PL (1) PL2509593T3 (xx)
PT (1) PT2509593T (xx)
RS (1) RS60336B1 (xx)
SG (1) SG181084A1 (xx)
SI (1) SI2509593T1 (xx)
TN (1) TN2012000256A1 (xx)
UA (1) UA109646C2 (xx)
WO (1) WO2011072138A2 (xx)
ZA (1) ZA201205056B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3215193T3 (pl) * 2014-11-06 2024-03-18 Pharmaessentia Corporation Reżim podawania pegylowanego interferonu

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20074024B (en) * 2002-01-18 2007-01-10 Biogen Idec Inc Polyalkylene glycol comprising a radical for conjugation of biologically active compound
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
ES2382124T3 (es) * 2007-09-04 2012-06-05 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este
GB0908393D0 (en) * 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method

Also Published As

Publication number Publication date
SI2509593T1 (sl) 2020-07-31
PL2509593T3 (pl) 2020-08-24
LT2509593T (lt) 2020-05-25
AR079369A1 (es) 2012-01-18
NZ600528A (en) 2014-01-31
PT2509593T (pt) 2020-04-21
JP5547816B2 (ja) 2014-07-16
RS60336B1 (sr) 2020-07-31
EA201200865A1 (ru) 2012-11-30
ES2786025T3 (es) 2020-10-08
BR112012014017A2 (pt) 2016-04-12
KR20120110105A (ko) 2012-10-09
MX2012006132A (es) 2012-06-19
WO2011072138A9 (en) 2011-10-06
WO2011072138A2 (en) 2011-06-16
EP2509593B1 (en) 2020-02-12
DK2509593T3 (da) 2020-05-11
MY169961A (en) 2019-06-19
UA109646C2 (uk) 2015-09-25
CA2782624C (en) 2016-11-01
JP2013513611A (ja) 2013-04-22
CL2012001503A1 (es) 2012-11-09
AU2010328067B2 (en) 2014-10-02
BR112012014017B1 (pt) 2021-10-26
EA022354B1 (ru) 2015-12-30
TN2012000256A1 (en) 2013-12-12
HRP20200678T1 (hr) 2020-10-02
EP2509593A4 (en) 2016-01-13
EP2509593A2 (en) 2012-10-17
SG181084A1 (en) 2012-07-30
CA2782624A1 (en) 2011-06-16
AU2010328067A1 (en) 2012-07-05
ZA201205056B (en) 2013-03-27
MA33913B1 (fr) 2013-01-02
MX337705B (es) 2016-03-15
HUE049051T2 (hu) 2020-09-28
CN102724980A (zh) 2012-10-10
KR101782084B1 (ko) 2017-09-26
US8617532B2 (en) 2013-12-31
EA022354B9 (ru) 2016-02-29
US20110262380A1 (en) 2011-10-27
CN102724980B (zh) 2014-10-15
IL220249A0 (en) 2012-07-31
CY1122901T1 (el) 2021-05-05

Similar Documents

Publication Publication Date Title
IL217208A0 (en) Novel conjugates, preparation thereof, and therapeutic use thereof
HK1171691A1 (zh) 血液凝結蛋白綴合物
LT2582728T (lt) Žmogaus antikūno vaisto konjugatai prieš audinių faktorių
GB0908957D0 (en) Therapeutic agents
GB0921731D0 (en) Theraputic uses
EP2588490A4 (en) SHORT AND D-AMINO ACID-CONTAINING POLYPEPTIDES FOR THERAPEUTIC CONJUGATES AND THEIR USES
HK1244426A1 (zh) 治療性蛋白質製劑
PL2496596T3 (pl) Peptydy terapeutyczne
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
PT2459224T (pt) Conjugados proteicos para coagulação sanguínea
GB0900484D0 (en) Therapeutic agent
HK1131039A1 (en) Pharmaceutical use of sophoricoside
HK1176015A1 (en) Therapeutic use of protein polymer conjugates
GB201010500D0 (en) Therapeutic conjugates
GB0910493D0 (en) Therapeutic agents
GB0921430D0 (en) Protein for therapeutic use
SI2459224T1 (sl) Konjugati krvnega koagulacijskega proteina
GB0922098D0 (en) Therapeutic use
GB0915801D0 (en) Theraputic treatment
GB0809936D0 (en) Therapeutic use of zolpidem
GB0819854D0 (en) Therapeutic use of zolpidem
GB0913300D0 (en) Therapeutic compounds and their use
GB0904261D0 (en) New therapeutic use
GB0911965D0 (en) Therapeutic agents
GB0919824D0 (en) Therapeutic agents